Treatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent MRI lesions after first-line treatment

EHA 2024

Leukemia

Real-world study showed that initiating the next treatment was significantly more common among patients treated with first-line acalabrutinib versus first-line ibrutinib

Leukemia

The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort

Haematologica

Saugues S, Lambert C, Daguenet E, Roth-Guepin G, Huguet F, Cony-Makhoul P, Ansah HJ, Escoffre-Barbe M, Turhan A, Rousselot P, Tchirkov A, Hamroun D, Hermet E, Pereira B, Berger MG

doi: 10.3324/haematol.2023.284860

Lung, Respiratory and Thoracic Cancer

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

Ann Oncol

Felip E, Cho BC, Gutiérrez V, Alip A, Besse B, Lu S, Spira AI, Girard N, Califano R, Gadgeel SM, Yang JC, Yamamoto S, Azuma K, Kim YJ, Lee KH, Danchaivijitr P, Ferreira CG, Cheng Y, Sendur MAN, Chang GC, Wang CC, Prabhash K, Shinno Y, Stroyakovskiy D, Paz-Ares L, Rodriguez-Cid JR, Martin C, Campelo MRG, Hayashi H, Nguyen D, Tomasini P, Gottfried M, Dooms C, Passaro A, Schuler M, Gelatti ACZ, Owen S, Perdrizet K, Ou SI, Curtin JC, Zhang J, Gormley M, Sun T, Panchal A, Ennis M, Fennema E, Daksh M, Sethi S, Bauml JM, Lee SH

doi: 10.1016/j.annonc.2024.05.541

SPECIAL REPORT

Lung, Respiratory and Thoracic Cancer

Navigating the Evolving Treatment Paradigm for Advanced EGFR-mutated NSCLC

Lung, Respiratory and Thoracic Cancer

Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study

Lung Cancer

Pons-Tostivint E, Ezzedine R, Goronflot T, Crequit P, Chatellier T, Raimbourg J, Bennouna J, Giroux Leprieur E, Porte M

doi: 10.1016/j.lungcan.2024.107887

SABCS 2024

Breast Cancer

PADMA: First-line palbociclib plus ET improves TFF and PFS versus chemotherapy in patients with high-risk HR-positive/HER2-negative metastatic breast cancer

Lung, Respiratory and Thoracic Cancer

Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1 ≥ 50 % progressing on first-line pembrolizumab

Lung Cancer

Stares M, Doyle E, Chapple S, Raynes G, MacDonald J, Barrie C, Laird B, MacKean M, Philips I

doi: 10.1016/j.lungcan.2024.107497

Genitourinary Cancer

Predicting response to intravesical BCG in high-risk non-muscle invasive bladder cancer using an artificial intelligence-powered pathology assay: development and validation in an international 12 center cohort

J Urol

Lotan Y, Krishna V, Abuzeid WM, Launer B, Chang SS, Krishna V, Shingi S, Gordetsky JB, Gerald T, Woldu S, Shkolyar E, Hayne D, Redfern A, Spalding L, Stewart C, Eyzaguirre E, Imtiaz S, Narayan VM, Packiam VT, O'Donnell MA, Li R, Baekelandt L, Joniau S, Zuiverloon T, Fernandez MI, Schultz M, Hensley PJ, Allison D, Taylor JA, Hamza A, Kamat A, Nimgaonkar V, Sonawane S, Miller DL, Watson D, Vrabac D, Joshi A, Shah JB, Williams SB

doi: 10.1097/JU.0000000000004278

COMMENTED

Genitourinary Cancer

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

★ 1 Recommended and commented by Prof. Dr Richard Cathomas, Faculty Member

Ann Oncol

Tannir NM, Albigès L, McDermott DF, Burotto M, Choueiri TK, Hammers HJ, Barthélémy P, Plimack ER, Porta C, George S, Donskov F, Atkins MB, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Tomita Y, Castellano D, Grünwald V, Rini BI, Jiang R, Desilva H, Federov V, Lee CW, Motzer RJ

doi: 10.1016/j.annonc.2024.07.727

Related content

Real-world study showed that initiating the next treatment was significantly more common among patients treated with first-line acalabrutinib versus first-line ibrutinib

The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

Navigating the Evolving Treatment Paradigm for Advanced EGFR-mutated NSCLC

Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study

PADMA: First-line palbociclib plus ET improves TFF and PFS versus chemotherapy in patients with high-risk HR-positive/HER2-negative metastatic breast cancer

Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1 ≥ 50 % progressing on first-line pembrolizumab

Predicting response to intravesical BCG in high-risk non-muscle invasive bladder cancer using an artificial intelligence-powered pathology assay: development and validation in an international 12 center cohort

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial